Hot Natural Products & Bioactive Compounds

BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.

Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.

Hot Products from BioCrick

Showing 673 - 680 of 9359 hot products

BioCrick hot natural products and bioactive compounds
Catalog No. Product Name
BCC3823 Nimodipine
L-type Ca2+ channel blocker.
BCC3826 Nocodazole
Microtubule inhibitor; inhibits mitosis. Also inhibits autophagosome-lysosome fusion. Enhances homology-directed repair (HDR) efficiency 9 to 31% (depending on cell cycle phase) and increases Cas9-mediated gene editing frequencies.
BCC3830 Orlistat
Hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A2, liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G1/S boundary in vitro. Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo.
BCC3831 Oxeladin Citrate
Oxeladin citrate is a cough suppressant, is a highly potent and effective drug used to treat all types of cough of various etiologies.
BCC3832 Oxethazaine
Oxethazaine is a topical anesthetic, in preventing acid-induced esophageal pain.
BCC3834 Paliperidone
Atypical antipsychotic; metabolite of risperidone . Exhibits high affinity for 5-HT2A receptors (Ki = 0.4 nM for cloned human 5-HT2A receptors). Also displays nanomolar affinity for human D2 receptors.
BCC3835 Pasiniazid
Pasiniazid is an anti-TB and anti-leprosy drug, used to treat various types of TB and leprosy.
BCC3837 PF-04691502
Potent and selective dual ATP-competitive PI 3-K/mTOR inhibitor (K<sub>i</sub> values are 1.6, 1.8, 1.9, 2.1 and 16 nM for human PI 3-K <span class='symbol'>&#948;</span>, <span class='symbol'>&#945;</span>, <span class='symbol'>&#947;</span>, <span class='symbol'>&#946;</span>, and mTOR, respectively). Displays no significant inhibitory activity at more than 80 protein kinases (concentration &#8805; 10 <span class='symbol'>&#956;</span>M) including hVps34, PI 3-K downstream kinases, and MAPK family members. Orally available. Induces robust cell cycle arrest at the G<sub>1</sub> phase in U87MG cancer cells and antitumor activity in SKOV3 ovarian cancer xenograft models.